218Novel thromboelastography point-of-care test detects all commercially available DOACs at therapeutic concentrations and classifies them as direct thrombin or factor Xa inhibitors with high consistency

Abstract

Introduction: The increasing use of direct oral anticoagulants (DOAC) calls for a point-of-care test to detect the presence and class of DOACs, especially in emergencies where reversal strategies are required and specific agents are now available. A novel thromboelastography cartridge, in conjunction with the analyser and software including a specific algorithm, detects all commercially available DOACs and distinguishes between anti-factor Xa (AFXa) and direct thrombin inhibitors (DTI).Purpose: To demonstrate the clinical utility of the new DOAC cartridge by establishing that all DOACs can be detected at trough and non-trough blood levels and to demonstrate consistency using repeat measurements.